Early-Life Gut Dysbiosis: A Driver of Later-Life Fibrosis?

J Invest Dermatol. 2017 Nov;137(11):2253-2255. doi: 10.1016/j.jid.2017.08.017.

Abstract

Using a novel mouse model of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendritic cells, Mehta et al. found that early-life antibiotic exposure resulted in increased later-life fibrosis in the skin and lungs. These observations advance the novel concept that gut microbiome alterations caused by early-life exposures may contribute to scleroderma pathogenesis, and warrant in-depth characterization and validation in complementary disease models.

Publication types

  • Comment

MeSH terms

  • Age Factors
  • Animals
  • Animals, Newborn
  • Anti-Bacterial Agents / pharmacology*
  • Autoimmune Diseases / physiopathology
  • Disease Models, Animal
  • Disease Progression
  • Dysbiosis / complications
  • Dysbiosis / pathology*
  • Fibrosis / immunology
  • Fibrosis / pathology
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / immunology
  • Mice
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / immunology
  • Pulmonary Fibrosis / pathology*
  • Scleroderma, Localized / etiology
  • Scleroderma, Localized / immunology*
  • Scleroderma, Localized / pathology*
  • Sensitivity and Specificity

Substances

  • Anti-Bacterial Agents